<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02997813</url>
  </required_header>
  <id_info>
    <org_study_id>IFM2014-05</org_study_id>
    <nct_id>NCT02997813</nct_id>
  </id_info>
  <brief_title>Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies</brief_title>
  <acronym>MOZOBIL</acronym>
  <official_title>Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-dose Cyclophosphamide Versus Plerixafor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone du Myelome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone du Myelome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective observational cohort database analysis. The study will review
      retrospectively the records of patients undergoing a first peripheral blood stem cell
      mobilization for multiple myeloma in the databases from approximately 15 hospitals which are
      part of the IFM collaborative group. Patient records will be divided into two groups of 50
      patients minimum, maximum 100 patients or up to the number of patient records that could be
      extracted. The first group of patients will have received plerixafor plus G-CSF without the
      administration of chemotherapy as a mobilization strategy and a second group of patients will
      have received cyclophosphamide plus G-CSF as a mobilization strategy.

      All consecutive patients with complete set of data (and who underwent apheresis) treated
      between 2009 and 2013 with G-CSF and plerixafor and all consecutive patients with complete
      data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and
      cyclophosphamide will be included.

      All data that will be analyzed will be extracted from the selected IFM institutions which are
      located in France.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total cost of stem cell mobilization procedure (including remobilisation if applicable)</measure>
    <time_frame>2009-2013</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of visits for administration of mobilizing agents</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (days) of administration of mobilizing agents</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agents used as mobilizing agents</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attainment of CD34+ target (yes, no) (min 2.106 cells/kg, ideal &gt;4.106cells/kg)</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days needed to meet CD34+ target level (min 2.106 cells/kg, ideal &gt;4.106cells/kg)</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">112</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Blood Stem Cell Transplant Failure</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>All consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The first group of patients will have received plerixafor plus G-CSF without the
        administration of chemotherapy as a mobilization strategy and a second group of patients
        will have received cyclophosphamide plus G-CSF as a mobilization strategy.

        All consecutive patients with complete set of data (and who underwent apheresis) treated
        between 2009 and 2013 with G-CSF and plerixafor and all consecutive patients with complete
        data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and
        cyclophosphamide will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematology patients diagnosed with Multiple Myeloma who are candidates for autologous
             hematopoietic stem cell transplantation (ASCT) upfront.

          -  Age &gt; 18 years

          -  Undergone prior successful peripheral blood stem cell mobilization with
             Cyclophosphamid or Plerixafor

        Exclusion Criteria:

          -  Age &lt; 18 years;

          -  Primary diagnosis other than Multiple Myeloma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Leleu, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Service des maladies du sang, Hôpital Huriez, CHRU, Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis Caillot, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Service d'Hématologie Clinique, Hôpital Le Bocage, CHU Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Deconinck, Pr</last_name>
    <role>Study Director</role>
    <affiliation>Hématologie, Hôpital Jean Minjoz, CHU Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Limat, Pr</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacie centrale, Hôpital Jean Minjoz, CHU Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Centre de Lutte Contre le Cancer (CLCC)</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Pitié Salpetriêre</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré Hématologie</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

